Clinical Trial

A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2026 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a multi-center, observational study aiming to develop an early screening multi-model for detecting lung cancer signals through the integration of imaging (non-contrast CT) and blood testing (cfDNA methylation).
Trial Details
NCT Number NCT07375979
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Collaborators: Shanghai Chest Hospital, Liaoning Cancer Hospital & Institute, The First Affiliated Hospital of Zhengzhou University, Yunnan Cancer Hospital, Shijiazhuang People's Hospital, The First Hospital of Jilin University
Conditions Lung Cancer
Enrollment 14,300 participants
Start Date 2026-02-05
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-29